Anticancer drug IT-139 presented at AACR Meeting 2018


Debora Wernitznig presented the latest findings on the mode of action of IT-139 at the Annual Meeting of the American Association of Cancer Research (AACR) April 14-18, 2018.

The ruthenium-based anticancer drug KP1339/IT-139 has been developed by the Bernhard Keppler Group of the Institute of Inorganic Chemistry in cooperation with the Medical University Vienna and the Research Cluster Translational Cancer Therapy Research. It is currently undergoing clincal studies in USA in cooperation with Intezyne, Inc. (Tampa, FL). 


In a 3-D colorectal cancer cell culture model, the active substance KP-1339 (IT-139) triggers characteristics that cause immunogenic cell death in the organism.